Correlation between Demographic Characteristic and Oxidized Low Density Lipoprotein (OxLDL-IgM and OxLDL-IgG) Antibodies levels in patients with Systemic Lupus Erythematosus Patients
DOI:
https://doi.org/10.32007/jfacmedbagdad.6612002Keywords:
Immunoglobulins G, Immunoglobulins M, ImmunogOxidized Low-Density Lipoprotein antibody, Obesity, Systemic Lupus ErythematosusAbstract
Background: Systemic Lupus Erythematosus (SLE) may affect one or more organ systems; as time goes on, other manifestations may start to appear. Musculoskeletal, cutaneous, renal, and endocrine systems are all involved in SLE. The nervous system, hematological, vascular, pulmonary, gastrointestinal, and ocular imbalance of the immune response and the production of autoantibodies such as anti-oxidized Low-Density Lipoprotein LDL antibodies have a clear impact on the body’s organs and the development of complications of the disease.
Objectives: To assess the levels of anti-oxLDL (IgM-Abs) and anti-oxLDL (IgG-Abs) as biomarkers for disease activity in SLE patients and their relationship to demographic characteristics.
Methods: The study comprised 100 SLE patients admitted to the Rheumatology Unit at Baghdad Teaching Hospital, age range (33.4 to 9.95) years, including 7 males and 93 females. An enzyme-linked immunosorbent Assay ELISA was used to measure the levels of serum oxLDL (IgM- Abs) and oxLDL (IgG-Abs).
Results: The results of the present study showed that there was a significant difference between the levels of anti-oxLDL IgM antibodies(Abs) in SLE patients in obese and non-obese groups since the levels of anti-oxLDL-IgM Abs in obese patients were (3.14 µg/L) and non-obese patients were (5.13 µg/L) (P=0.005), while in SLE patients with Diabetes Mellitus (D.M.), the levels of anti-ox LDL-IgM Abs were (3.80 µg/L) and in SLE patients with no DM were (5.13 µg/L). Also, the results showed that there were no significant differences between levels of anti-oxLDL IgG Abs in obese patients with SLE (6.28 µg/L) and non-obese patients with SLE (10.25µg/L) P > 0.05.
Conclusion: There was a significant difference between levels of anti-oxLDL IgM Abs in obese and non-obese patients with SLE, and no significant differences between the levels of anti-oxLDL IgG Abs in the same groups of patients.
Received Oct.2022
Revised: Nov.2023
Accepted Dec. 2024
Published July 2024
Downloads
References
1. Gustafsson, JT. and Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus, Autoimmunity, 2014;47(2): 67-76. https://doi.org/10.3109/08916934.2013.856005. DOI: https://doi.org/10.3109/08916934.2013.856005
2. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006 May;15(5):308-18. https://doi.org/10.1191/0961203306lu2305xx. DOI: https://doi.org/10.1191/0961203306lu2305xx
3. Perricone C, Versini M, Ben-Ami D, et al. Smoke, and autoimmunity: The fire behind the disease, Autoimmunity Reviews,2016;15(4): 354-74. https://doi.org/10.1016/j.autrev.2016.01.001. DOI: https://doi.org/10.1016/j.autrev.2016.01.001
4. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation, and autoimmunity', JAut,2010;34(3): J258-J265. https://doi.org/10.1016/j.jaut.2009.12.003. DOI: https://doi.org/10.1016/j.jaut.2009.12.003
5. Tektonidou MG, Kravvariti E, Konstantonis G, et al. Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis', Autoimmunity Reviews,2017;16(3): 308-12. https://doi.org/10.1016/j.autrev.2017.01.009. DOI: https://doi.org/10.1016/j.autrev.2017.01.009
6. Tedeschi SK, Barbhaiya M, Malspeis S, et al. Obesity and the risk of systemic lupus erythematosus among women in the Nurses’ Health Studies. InSeminars in arthritis and rheumatism 2017 Dec 1 (Vol. 47, No. 3, pp. 376-383). WB Saunders.. https://doi.org/10.1016/j.semarthrit.2017.05.011. DOI: https://doi.org/10.1016/j.semarthrit.2017.05.011
7. Chambers SA, Charman SC, Rahman A, Isenberg DA. Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Annals of the rheumatic diseases. 2007 Sep 1;66(9):1173-7. https://doi.org/10.1136/ard.2006.062984. DOI: https://doi.org/10.1136/ard.2006.062984
8. Li H, Li DQ, Li XX, Wang LQ. The association between oxidized low-density lipoprotein antibodies and hematological diseases. Lipids in health and disease. 2016 Nov 8;15(1):190. https://doi.org/10.1186/s12944-016-0360-y. DOI: https://doi.org/10.1186/s12944-016-0360-y
9. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis & Rheumatism. 2001 Oct;44(10):2331-7. https://doi.org. DOI: https://doi.org/10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I
10. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. AJE. 1997 Mar 1;145(5):408-15. https://doi.org/10.1093/oxfordjournals.aje.a009122. DOI: https://doi.org/10.1093/oxfordjournals.aje.a009122
11. Pons-Estel GJ, Gonzalez LA, Zhang J, Burgos PI, et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology. 2009;48(7):817-22. https://doi.org/10.1093/rheumatology/kep102. DOI: https://doi.org/10.1093/rheumatology/kep102
12. Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. JCDD. 2019 Apr 27;6(2):19. https://doi.org/10.3390/jcdd6020019. DOI: https://doi.org/10.3390/jcdd6020019
13.Golder V, Tsang-A-Sjoe MW. Treatment targets in SLE: remission and low disease activity state. Rheumatology. 2020 Dec;59(Supplement_5):v19-28. https://doi.org/10.1093/rheumatology/keaa420. DOI: https://doi.org/10.1093/rheumatology/keaa420
14. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism: Arthritis & Rheumatism, 1982; 25: 1271-1277. https://doi.org/10.1002/art.1780251101. DOI: https://doi.org/10.1002/art.1780251101
15. Petri M. Infection in systemic lupus erythematosus. Rheumatic Disease Clinics of North America. 1998 May 1;24(2):423-56. https://doi.org/10.1016/S0889-857X(05)70016-8. DOI: https://doi.org/10.1016/S0889-857X(05)70016-8
16. Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. The American journal of medicine. 1992 Nov 1;93(5):513-9. https://doi.org/10.1016/0002-9343(92)90578-Y. DOI: https://doi.org/10.1016/0002-9343(92)90578-Y
17.Nived O, Ingvarsson RF, Jöud A, Linge P, et al. Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE. Lupus science & medicine. 2020 Jun 24;7(1).https://doi.org/10.1136/lupus-2020-000398. DOI: https://doi.org/10.1136/lupus-2020-000398
18. Munguia-Realpozo P, Mendoza-Pinto C, Benito CS, et al. Systemic lupus erythematosus and hypertension. Autoimmunity reviews. 2019 Oct 1;18(10):102371. https://doi.org/10.1016/j.autrev.2019.102371. DOI: https://doi.org/10.1016/j.autrev.2019.102371
19. Patterson SL, Schmajuk G, Jafri K, et al. Obesity is independently associated with worse patient‐reported outcomes in women with systemic lupus erythematosus. Arthritis care & research. 2019 Jan;71(1):126-33. https://doi.org/10.1002/acr.23576. DOI: https://doi.org/10.1002/acr.23576
20. Rizk A, Gheita TA, Nassef S, et al. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis. International journal of rheumatic diseases. 2012 Jun;15(3):261-7. https://doi.org/10.1111/j.1756-185X.2011.01698. DOI: https://doi.org/10.1111/j.1756-185X.2011.01698.x
21. Segura BT, Bernstein BS, McDonnell T, et al. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology. 2020 Mar 1;59(3):524-33. https://doi.org/10.1093/rheumatology/kez516. DOI: https://doi.org/10.1093/rheumatology/kez516
22. Angelica Sinicato N, Aparecida da Silva Cardoso P, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Current cardiology reviews. 2013 Feb 1;9(1):15-9. https://doi.org/10.2174/157340313805076304. DOI: https://doi.org/10.2174/157340313805076304
23. Masztalewicz M, Nowacki P, Kotlęga D, et al. Anti-oxLDL antibodies are clinically insignificant for stroke patients. Neurological Research. 2014 Jan 1;36(1):86-91.
https://doi.org/10.1179/1743132813Y.0000000268. DOI: https://doi.org/10.1179/1743132813Y.0000000268
24. Omar NN, Hefnawy MH, Mohamed F, Heider NM, Hamed HI. Assessment of oxLDL, anti-oxLDL antibodies and lipoprotein-associated phospholipase A2 as cardiovascular risk markers in obese adolescents with and without T1DM. B-FOPCU. 2017 Dec 1;55(2):325-331. https://doi.org/10.1016/j.bfopcu.2017.05.002. DOI: https://doi.org/10.1016/j.bfopcu.2017.05.002
25. van den Berg VJ, Vroegindewey MM, Kardys I, et al. Anti-oxidized LDL antibodies and coronary artery disease: a systematic review. Antioxidants. 2019 Oct 15;8(10):484. https://doi.org/10.3390/antiox8100484. DOI: https://doi.org/10.3390/antiox8100484
26. Shiri-Sverdlov R, Dos Reis IM, Oligschlaeger Y, et al. The influence of a conjugated pneumococcal vaccination on plasma antibody levels against oxidized low-density lipoprotein in metabolic disease patients: a single-arm pilot clinical trial. Antioxidants. 2021 Jan 18;10(1):129. https://doi.org/10.3390/antiox10010129. DOI: https://doi.org/10.3390/antiox10010129
27. Alouffi S, Faisal M, Alatar AA, Ahmad S. Oxidative modification of LDL by various physicochemical techniques: its probable role in diabetes coupled with CVDs. BioMed Research International. 2018;2018(1):7390612. https://doi.org/10.1155/2018/7390612. DOI: https://doi.org/10.1155/2018/7390612
28. Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. Journal of Atherosclerosis and Thrombosis. 2013;20(10):743-54. https://doi.org/10.5551/jat.19281. DOI: https://doi.org/10.5551/jat.19281
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Nusaibah K. Al-Zubaidi, Suha A. Al-Fakhar , Mohammad H. Al-Osami
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution 4.0 International license..
